Pfizer and DNA testing firm 23andMe agreed to collaborate to uncover possible genetic mutations associated with inflammatory bowel disease. 23andMe will analyze saliva samples of 10,000 people with either Crohn's disease or ulcerative colitis. "Our research objective is to understand the genetic associations found between IBD patients' DNA and their disease, and apply this understanding to Pfizer's drug development efforts," 23andMe said in a prepared statement.

Related Summaries